Influenza, commonly known as the flu, is an infectious disease of birds and mammals caused by an RNA virus of the family Orthomyxoviridae, the influenza viruses. In people, common symptoms of influenza are fever, sore throat, muscle pains, severe headache, coughing, and weakness and fatigue.

Statement - Label changes for Tamiflu - Roche

Flu :: Statement - Label changes for Tamiflu - Roche

Tamiflu (oseltamivir phosphate) was demonstrated in clinical trials to be a safe and effective medication for influenza prevention and treatment. Tamiflu was approved in 1999 and has been used by more than 42 million people in over 80 countries.

Roche continuously reviews post-marketing safety information and provides regular updates to the regulatory agencies. Based upon reports received over the last influenza season Roche has agreed that the Tamiflu label in the US will be revised to include reports of neuropsychiatric events such as self-injury and delirium in patients with influenza. Reports of neuropsychiatric events in patients taking oseltamivir are very rare based on usage, and a causal relationship between the use of oseltamivir and the likelihood of neuropsychiatric events in influenza patients cannot be established.

In 2005, 103 psychological reports during treatment of influenza with Tamiflu were received, including 5 deaths. These events are extremely rare in relation to the number of patients treated during the influenza season. Based upon the information presented by the FDA we calculate that:

approximately 1 in 100'000 patients experienced psychological disorders
approximately 1 out of 2 million patients treated died

None of these events could be established to have been caused by Tamiflu.

Phase III pivotal trials conducted by Roche found similar reports of neurologic and psychiatric events in pediatric influenza patients being treated with Tamiflu and those receiving no treatment. In addition, a recent review of a US claims database showed no differences in the incidence of neuropsychiatric events between flu patients treated with Tamiflu and those who were not treated.

Influenza itself is a severe disease. High fever, which is a typical symptom of influenza, has been associated with neuropsychaitric disorders including hallucination or delirium.

The well-being of patients and the safe and effective use of our medications is a priority for Roche. Roche continues to monitor the safety of Tamiflu through established reporting mechanisms and notify regulatory authorities of adverse events in line with regulatory requirements.

Recently posted related articles on Flu :

1. Bird Flu :: Need for preparedness for potential flu pandemic
2. Flu :: No Vacation for Flu Virus
3. Bird Flu :: 12 year Indonesian boy dies of bird flu
4. Foot and Mouth Disease :: Smiths Detection to launch a portable diagnostic system for foot-and-mouth disease and avian flu
5. Bird Flu :: Grid computing offers new hope in race against bird flu
6. Bird Flu :: Mutated bird flu virus more infectious to humans
7. Bird Flu :: Researchers identify key step bird flu virus takes to spread readily in humans
8. Bird Flu :: Avian influenza – situation in Indonesia – update 17
9. Bird Flu :: Depopulation of birds complete at Saskatchewan farm, Canada
10. Vaccine :: American College of Physicians recommends flu vaccination for health-care workers